Would you be comfortable using a JAK inhibitor in a patient with baseline thrombocytosis?
Would the etiology of the thrombocytosis play a role in your decision-making?
Answer from: at Academic Institution
Knowing the etiology of this patient's thrombocytosis is a critical piece of information required before determining whether a JAK- inhibitor drug could be safely prescribed. Mutations in JAK-2 are responsible for several myelodysplastic disorders, some of which present with thrombocytosis. Therefor...
Sign in or Register to read more